BIOA|EPS -$2.24|Rev $9.0M|Internet Loss $80.6M
Firm Overview
BioAge Labs is a clinical-stage biopharmaceutical firm that develops therapeutic product candidates for metabolic ailments by focusing on human growing old biology.
Key Monetary Figures
For the 12 months ended December 31, 2025, the corporate reported a collaboration income of $9.0 million. The online loss per share, representing EPS, was $(2.24). The full web loss for the 12 months was $80.6 million.
Further Monetary Insights
Analysis and growth bills reached $73.9 million in 2025. As of the tip of the 12 months, BioAge maintained roughly $285.1 million in money, money equivalents, and marketable securities.
This text was generated with the help of AI expertise and reviewed for accuracy. AlphaStreet could obtain compensation from firms talked about on this article. This content material is for informational functions solely and shouldn’t be thought-about funding recommendation.
